Inmune Bio, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how Inmune Bio performed this year. My goal is to break down their complex filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Inmune Bio is a clinical-stage biotech company. This means they are in the lab-heavy phase of inventing medicines. They do not sell products to the public yet. Instead, they focus on proving their treatments work through clinical trials. They aim to "reprogram" the immune system to fight diseases like Alzheimer’s, cancer, and a rare skin condition called RDEB. To date, the company has generated zero revenue from product sales.

2. The Big News: CORDStrom™

The biggest update is the progress of their lead drug, CORDStrom, which treats RDEB—a painful pediatric skin disease.

• The Results: In a Phase 2 trial, the drug proved safe. Patients reported fewer "itchy days" and saw their chronic wounds heal better. These wounds are the main cause of health issues in RDEB patients.
• The Plan: They plan to file for approval in the UK, EU, and U.S. by late 2026. These filings will rely on data from their ongoing studies.
• The Perks: The FDA granted them "Orphan Drug" status. This provides tax credits, waives over $3 million in application fees, and grants seven years of market exclusivity. This blocks generic competition for that period.

3. The Alzheimer’s Update: XPro

The company recently finished a Phase 2 trial for their Alzheimer’s drug, XPro.

• The Reality Check: The trial of 190 patients did not meet its main goal of improving cognitive function across the whole group. However, a follow-up look at the data showed that patients with high levels of brain inflammation did show a slowing of cognitive decline.
• The Strategy: Because of these mixed results, Inmune Bio will not fund further XPro development alone. They are now looking for a "strategic partner"—a larger pharmaceutical company with the cash to fund the massive, expensive Phase 3 trials—to take the lead.

4. Financial Health: The "Burn"

With no products on the market, the company has no sales revenue. They "burn" cash to pay for research and administrative costs, which totaled about $22.5 million last year.

• How they survive: They sell more shares of stock to raise money. This reduces your ownership percentage in the company. The number of shares held by investors has grown significantly over the last two years to keep the company running.
• The Bottom Line: By stopping independent work on XPro and their cancer platform, the company is trying to save cash. They have about $15 million in cash, which they expect will last into the second half of 2025. They will likely need to raise more money or find a partner before their 2026 goals.

5. Key Risks

• Clinical Failure: If CORDStrom fails in later, larger trials, the company’s value could drop significantly.
• Funding: They are not self-sustaining. If they cannot find a partner or raise more cash, operations could stall.
• Partnership Dependency: Their success with XPro now depends entirely on finding a partner. There is no guarantee they will find one or that the deal will be good for shareholders.

6. The Bottom Line

Inmune Bio is a high-risk, high-reward bet. They have shifted their focus almost entirely to CORDStrom while looking for partners for their other projects. The next 12–18 months are critical as they head toward their 2026 deadlines. Investors should expect more shares to be issued, which will reduce your ownership stake, as the company bridges its funding gap.

---

Investor Checklist:

• Timeline: Are you comfortable waiting until late 2026 for potential regulatory filings?
• Dilution: Are you prepared for the possibility that the company will issue more shares to fund operations?
• Partnership: Does the reliance on finding a pharmaceutical partner for XPro align with your risk tolerance?